文档介绍：: .
解放军医学杂 (DAA)两个时代，总体来说，通过抗病毒治疗获得持续病毒学应答(SVR)能够降低 HCV 相
关的 HCC 发生率。但近年来一些关于 DAA 治疗可能增加 HCC 发生率或复发率的报道引起
了学者们的广泛关注，本文对经 PR 及 DAA 治疗后导致 HCC 发生或复发，以及 HCC 发生
危险因素的相关文献进行综述，探讨 DAA 治疗后发生 HCC 的机制以及 HCC 对 DAA 疗效
的影响，帮助临床医生确定启动抗病毒治疗的时机及实施个体化管理。
[关键词] 丙型肝炎病毒；PR 疗法；直接抗病毒治疗；肝细胞癌
[中图分类号] [文献标志码] A [DOI] .0577-
Research progress on the association of antiviral therapy with
HCV-hepatocellular carcinoma
Deng Ya1,2, Wang Chun-Yan2, Ji Dong1,2*
1The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515,
China; 2Senior Department of Hepatology, the Fifth Medical Center of Chinese PLA General
Hospital, Beijing 100039, China
* Corresponding author, E-mail:******@
This work was supported by Medical Big Data and Artificial Intelligence Development Fund
of Chinese PLA General Hospital (2019MBD-024)
[Abstract] Chronic hepatitis C virus (HCV) is a worldwide epidemic and the main cause of
liver cirrhosis and hepatocellular carcinoma (HCC). The treatment of anti-HCV has gone through
two eras of pegylated interferon-α plus ribavirin (PR therapy) and direct-acting antiviral agent
(DAA). Generally, achieving a sustained virological response (SVR) can reduce the incidence of
HCC through antiviral treatment. In recent years, increasing researchers pay more attention to the
issue whether DAA treatment might increase the risk of HCC o